Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.16
+0.33 (1.85%)
At close: Jun 24, 2026, 4:00 PM EDT
18.16
0.00 (0.00%)
After-hours: Jun 24, 2026, 5:54 PM EDT

Avalo Therapeutics Revenue

In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%.

Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
16,206.23
Revenue / Employee
$1,788
Employees
33
Market Cap
956.17M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202559.00K-382.00K-86.62%
Dec 31, 2024441.00K-1.48M-77.08%
Dec 31, 20231.92M-16.13M-89.34%
Dec 31, 202218.05M12.65M234.40%
Dec 31, 20215.40M-1.30M-19.42%
Dec 31, 20206.70M-51.35K-0.76%
Dec 31, 20196.75M-278.03K-3.96%
Dec 31, 20187.03M-20.78M-74.73%
Dec 31, 201727.81M26.66M2,312.26%
Dec 31, 20161.15M--
Dec 31, 2015---
Dec 31, 2014---
Dec 31, 2013---
Dec 31, 201282.76K--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Pharming Group369.49M
Geron196.12M
Arbutus Biopharma191.45M
Kura Oncology71.64M
Janux Therapeutics13.73M
Odyssey Therapeutics1.06M
Revenue Rankings